



Joint Event

2nd Edition of Cell & Gene Therapy World Conference and 2nd Edition of Cancer R&D World Conference

SEPTEMBER 21-23, 2026

**Hilton Garden Inn Miami Dolphin Mall,
Miami, Florida, USA
@ Hybrid (In-Person & Virtual)**

SILVER SPONSOR



EXHIBITOR



EXHIBITOR




SCIENTIFIC PROGRAM

An orange abstract shape with a wavy top edge, containing the title text.

About Precision Global Conferences

Precision Global Conferences (PGC) stands as a trusted leader in international scientific and industry event management, with a proven track record of delivering over thirty world-class conferences across premier innovation hubs in the United States, Europe, and Asia — including Singapore, Miami, San Francisco, Boston, Barcelona, Paris, and Thailand. We specialize in creating high-impact platforms that unite life science innovators, leading researchers, distinguished industry experts, and forward-thinking technology companies under one roof.

A large orange abstract shape with a wavy top edge, occupying the bottom half of the page.

About Silver Sponsor

Illumina is a global leader in genomics and precision health, advancing how researchers, clinicians, and healthcare organizations understand human biology through DNA sequencing and array-based technologies. Founded in 1998 and based in San Diego, Illumina has accelerated genomic discovery and expanded access to precision medicine worldwide. Its platforms drive progress in oncology, reproductive health, genetic disease research, infectious disease detection, and population genomics, enabling more personalized and effective healthcare. Operating in over 165 countries and committed to scientific collaboration, Illumina focuses on accessibility, accuracy, and scalability. Guided by a vision to unlock the power of the genome for humanity, the company is dedicated to improving global health through innovation and transformative technologies.

The Illumina logo, featuring the word "illumina" in a lowercase, sans-serif font. The letter "i" is orange, and the remaining letters "llumina" are dark grey. The logo is positioned on a white background, with a large, light orange abstract shape behind it.

About Exhibitor

Bionova Scientific® is a leading biologics Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacturing of recombinant protein therapeutics using mammalian cell culture technologies. Backed by the global strength of Asahi Kasei, Bionova combines scientific excellence, advanced bioprocessing capabilities, and an agile approach to accelerate the journey from concept to cure. From cell line development through commercial manufacturing, Bionova partners with biopharmaceutical innovators to deliver robust, high-quality biologics and bring life-changing therapies to patients faster.



About Exhibitor

Founded in 2017 in Oregon, AICON-BIO began by providing comprehensive immunology solutions, specializing in microbiology, ELISA, rapid tests, and IVD raw materials. The company later expanded into molecular diagnostics with a focus on women's and animal molecular testing. In 2021, AICON-BIO expanded into regenerative biotechnology and cell and gene therapy, specializing in mesenchymal stem cell (MSC) culture technologies. In 2023, the company introduced NeoPL Human Platelet Lysate, a serum-free growth supplement for advanced cell culture, as well as customized multi-chamber cell culture systems to support biotech research and pharmaceutical development. Today, AICON-BIO combines diagnostic innovation with regenerative biotechnology to deliver reliable, high-quality solutions that advance scientific research and clinical practice

AICON-BIO®

Our Organizing Committee Members



Raghu Kalluri

Professor and Chairman of the
Department of Cancer Biology at the
University of Texas MD Anderson
Cancer Center, USA



Pratima Cherukuri

GM & SVP, Bionova Scientific, USA



Rob Tressler

CSO, Excellos, USA



Raphaël G. Ognar

President, CEO, Co-Founder &
Chairman, NKILT Therapeutics, Inc.,
USA



Mary Schaheen

President, Prevail Partners LLC, USA



Nicolas Thevenet

Chief Operations Manager, Euraxi
Pharma, France



Raluca Dumitru

VP of Scientific Affairs, Discovery Life
Sciences, USA



Guobao Chen

WuXi AppTec, USA



Shi-Jiang (John) Lu

HebeCell, USA

Our Keynote Speakers



Pratima Cherukuri
GM & SVP, Bionova Scientific, USA



Mary Schaheen
President, Prevail Partners LLC, USA



Raluca Dumitru
VP of Scientific Affairs, Discovery Life Sciences, USA



Raphaël G. Ognar
President, CEO, Co-Founder & Chairman, NKILT Therapeutics, Inc., USA



Raghu Kalluri
Professor and Chairman of the Department of Cancer Biology at the University of Texas MD Anderson Cancer Center, USA



**Leena Mol
Thuruthippallil**
Kyfora Bio, Horsham, USA



Guobao Chen
WuXi AppTec, USA



Jeffrey Chen
Senior Consultant
NuveraConsulting, USA



Davide Prosperi
University of Milano-Bicocca, Italy



Miriam Colombo
University of Milano-Bicocca, Italy



Rocky Tuan
The Chinese University of Hong Kong, Hong Kong



Prasun Chakraborty
Genevation LTD, UK



Ilya Tsimafeyev
BUCARE, USA



Shi-Jiang (John) Lu
HebeCell, USA



Jamal Zidan
Oncology Division, Ziv Medical Center, Israel

FINAL PROGRAM

Timing is as per Eastern Time (ET)

DAY 1 In-Person Presentations

08:30-08:50 **Registrations** **Moderator: Tatiana Zhelninova Bosch**

08:50-09:00 **Opening Ceremony & AV Setup**

Keynote Presentations

09:00-09:30 **Title: Plasmid to Patient: Building Scalable DNA Platforms for Cell & Gene Therapy**
Pratima Cherukuri, GM & SVP, Bionova Scientific, USA

09:30-10:00 **Title: How Best to Communicate with Investors: You Can Trace Every Business Problem to a Communications Problem**
Mary Schaheen, President, Prevail Partners LLC, USA

10:00-10:30 **Group Photo**
Coffee Break @ Lobby

Oral Presentations

10:30-11:00 **Title: Source Matters: Optimizing Donor Inputs for Allogeneic Manufacturing**
Raluca Dumitru, VP of Scientific Affairs, Discovery Life Sciences, USA

11:00-11:30 **Title: From Innovation to Global Impact: Building Off-the-Shelf Cell Therapy with Scalable Allogeneic Technologies**
Raphaël G. Ognar, President, CEO, Co-Founder & Chairman, NKILT Therapeutics, Inc, USA

11:30-12:00 **Title: Reimagining Transient Transfection: A Smarter Path to Efficient and Scalable AAV Manufacturing**
Leena Mol Thuruthippallil, Kyfora Bio, USA

12:00-12:30 **Title: The Integrated Platform for In Vivo CAR Discovery and Development**
Guobao Chen, WuXi AppTec, USA

12:30-1:00 **Title: General Keynote Talk**
Rob Tressler, CSO, Excellos, USA

01:00-01:40 **Lunch @ Lobby**

Keynote Presentations

01:40-02:00 **Title: General Keynote Talk**
Nektaria Andronikou, Strategic Scientific Leader in Advanced Therapies, Thermo Fisher Scientific, USA

02:00-02:30 **Title: Manufacturing of Autologous CAR T Cell Therapies**
Sree Deshpande, Scientist, Cytiva, USA

02:30-03:00 **Title: Enhancing Treatment Center Management Through Operational Archetyping A Strategic Approach for Cell and Gene Therapies**
Jeffrey Chen, Senior Consultant Nuvera Consulting, USA

FINAL PROGRAM

03:00-03:30	Title: Anticancer Effects of H-Ferritin-Conjugated Monoclonal Antibodies in 3D Tumor Models Davide Prosperi, University of Milano-Bicocca, Italy
03:30-04:00	Title: Lipid Nanoparticles for Targeted RNA Delivery Through A Biomimetic Cancer Cell Membrane Coating Miriam Colombo, University of Milano-Bicocca, Italy
04:00-04:20	Coffee Break @ Lobby
04:20-04:50	Title: From Joint Regeneration to Joint on a Chip: MiniJoint Rocky Tuan, The Chinese University of Hong Kong, Hong Kong
04:50-05:20	Title: Between the Breakthrough and the Oath: Cell Therapy, Artificial Intelligence and the Physician of the Future Tatiana Zhelninova Bosch, International Medical Director, VAANAA International Longevity Medical Clinic, Thailand
05:20-05:50	Title: Beyond the Grant: New Capital Pathways for Translational Cancer Research Mark Stoner, CEO & Cofounder of BioCrowd, USA
05:50-06:30 Poster Presentations	
Poster-1	Title : Enhancing Preclinical Insights in Immuno-Oncology with Humanized Mice Emilie Heckel, Oncodesign Services, France
Poster-2	Title: Evaluation Of Cellular Uptake and Cytotoxic Activity of Novel 1,3 Selenazole 2 One Derivatives Incorporated into Self Emulsifying Drug Delivery Systems in Breast Cancer Cells Robert Czarnomysy, Medical University of Bialystok, Poland
Poster-3	Title: Prolidase Dependent Chemotherapy Resistance in MCF7 Breast Cancer Cells: The Role of Oxidative Stress Arkadiusz Surazynski, Medical University of Bialystok, Poland
Poster-4	Title: Gasdermin As Molecular Signature and Predictor of Adult Type Diffuse Gliomas Severity and Grading Justyna Hermanowicz, Medical University of Bialystok, Poland
Poster-5	Title: Virus Specific Metabolic Remodeling Enables Discrimination of Dengue and Zika Virus Infections in Human iPSCs Tahira Fatima, Staff Fellow CBER/OTP/OCTHT/DCT2/TVBB US Food and Drug Administration ,New Hampshire Avenue Silver Spring,USA

FINAL PROGRAM

DAY 2 - In-Person Presentations

08:30-09:00 **AV Setup** Moderator: Tatiana Zhelninova Bosch

Keynote Presentations

09:00-09:30 **Title: From Biopsy to Injection in 14 Days: AI Driven Personalized Cancer Vaccines at Clinical Speed**

Prasun Chakraborty, Genevation LTD, UK

09:30-10:00 **Title: A Novel FGFR1 Targeting Monoclonal Antibody, OM RCA 01, Demonstrates Robust Antitumor Efficacy and Enhances Immune Checkpoint Blockade in Preclinical Models**

Ilya Tsimafeyeu, BUCARE, USA

10:00-10:30 **Title: Comparative Effectiveness of Olaparib Between Real-World Clinical Practice and RCTs in Advanced/Metastatic Ovarian Cancer with a BRCA Mutation**

Jamal Zidan, Oncology Division, Ziv Medical Center, Israel

10:30-11:00

Group Photo
Coffee Break @ Lobby

Oral Presentations

11:00-11:20 **Title: An Integrate Comprehensive In Vitro and In Vivo Strategies for Antibody Drug Conjugate Development**

Ismahene Benzaid Manseur, Oncodesign Services, France

11:20-11:40 **Title: MicroRNA Driven Precision Oncology and Immune Reprogramming in Mesothelioma**

Anand Singh, National Cancer Institute, NIH, USA

11:40-12:00 **Title: Substrate Elasticity as a Modulator of Chemotherapy Response in the Heterogeneous WC256 Rat Mammary Carcinoma Cell Line**

Daniel Dziob, Jagiellonian University Medical College, Poland

12:00-12:20 **Title: From Airway Epithelium to Cancer Stem Cells: Modeling Tobacco Smoke-Induced Reprogramming in SCLC**

Sudheer Kumar Gara, National Cancer Institute, NIH, USA

12:20-12:40 **Title: Novel Gene Editing Technologies and Emerging Biosecurity Threats**

Carolyn Brokowski, University of CT, USA

12:40-01:00 **Title: Novel Gene Editing Technologies and Emerging Biosecurity Threats**

Joanne, University of CT, USA

01:00-02:00

Lunch @ Lobby

02:00-02:20 **Title: Potential of Exosomal miRNAs in Early Diagnosis of Colorectal Cancer**

Przemyslaw Panek, Institute of Tuberculosis and Lung Diseases, Poland

02:20-02:40 **Title: Seeing the Invisible: How RNA Extraction and Library Prep Shape Viral Read Recovery in RNA-Seq**

Sayma Afroj, FDA / Auburn University, USA

FINAL PROGRAM

02:40-03:00	Title: Evaluation of Spliceosomal Protein H1/H2-Mediated Changes in the Immunomodulatory Properties of Melanoma-Derived Exosomes Vladimir Beljanski, Nova Southeastern University, USA
03:00-03:20	Title: Mechanism of Action Studies of Novel Spliceosomal Modulators In Melanoma Dmitriy Minond, Nova Southeastern University, USA
03:20-03:40	Title: The Importance of Physical Activity in the Prevention of Cancer Jaroslav Novak, University Hospital and Medical Faculty of Charles University, Czech Republic
03:40-04:00	Title: Navigating ATMP Regulation in Saudi Arabia: From Clinical Trial Authorization to Marketing Approval Mana Alshehri, PhD, ABRM,BCBBS,CABP,Saudi Arabia
04:00-04:20	Coffee Break @ Lobby
04:20-04:40	Title: The Application Allogeneic Mesenchymal Stromal Cells In Combination with Autologous Fibrin Gel For Mine Blast Trauma During Wartime Polina, DEVA CLINIQUE LLC, Ukraine
04:40-05:00	Title: From Thousands of Labels to Dozens: Label-Efficient Breast Cancer Histopathology Using Pathology Foundation Models and Vision Language Zero Shot Diagnosis Kirti Harsha, Indian Institute of Technology Roorkee, India
05:00-05:20	Title: Validated Replication-Competent Lentivirus (RCL) Monitoring Test Method for Nonclinical, Clinical, and CLIA studies Lily Kahsai Golden,Labcorp, Greenfield, Indiana,USA

Closing Ceremony

DAY 3 - Virtual Presentations

08:30-9:00 **AV Setup**

Keynote Presentations

09:00-09:30 **Title: Cancer Without Disease: Combining The Concept of Healthy Living and Aging with Strategies to Prevent Malignant Disease of Cancer**

Raghu Kalluri, Professor and Chairman of the Department of Cancer Biology at the University of Texas MD Anderson Cancer Center, USA

09:30-10:00 **Title: Revolutionizing Patient Access Through Decentralized European Research**

Nicolas Thevenet, Chief Operations Manager, Euraxi Pharma, France

10:00-10:30 **Title: ProtoNK Cells from Pluripotent Stem Cells for Treatment of Metastatic Cancers**

Shi-Jiang (John) Lu, HebeCell, USA

Oral Presentations

10:30-11:00 **Title: Muse Cell Exosomes: A New Frontier in Regenerative Medicine**

Tucson Dunn, ExoGrade, USA

11:00-11:30 **Title: Next Steps in the Generations of CAR T Therapies and Beyond**

Boris Pokhil, CromBIO, Russian Federation

11:30-12:00 **Title: Evolutionary Game Theory in Blockchain-Enabled Oncology Clinical Trial Management**

Prasad Kothari, Independent Researcher, India

12:00-12:30 **Title: Efficacy of distinct PD1 Inhibitors Plus Chemotherapy in Locally Advanced Head and Neck Cancer**

Xiang Zhang, The First Affiliated Hospital of Chongqing Medical University, China

12:30-01:00 **Title: Efficacy and Safety of Different Dosages of Anlotinib Combined with PD 1 Monoclonal Antibody in the Treatment of Advanced Non Small Cell Lung Cancer**

Juan Jiang, The First Affiliated Hospital of Chongqing Medical University, China

01:00-02:00 **Lunch Break**

02:00-02:30 **Title: Epidimin A Prevents Glioblastoma Growth and Invasion**

Erick Zecena & Michael Mildner, Noorda College of Osteopathic Medicine, USA

02:30-03:00 **Title: Elucidating a Plasmid Partition Driven Bacterial Density Oscillational Mechanism**

Jie Li, Shenzhen Institute of Advanced Technology, china

03:00-03:30 **Title: Developing a Next-Generation In Vitro Human BBB Model to Predict TCE-Mediated BBB Disruption and ICANS Risk**

Chun Huang, Johnson & Johnson, USA

03:30-04:00 **Title: Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered Organelle Vulnerabilities in HER2- Positive Breast Cancer Cells**

Shahnaz Salamat, University of Genova, Italy

FINAL PROGRAM

04:00-04:30

Title: Patient Derived Organoids (PDOs) as a Platform for Deciphering Breast Cancer Heterogeneity

Andreia Filipa Cruz, UCAM, Spain

Notes:

Notes:

UPCOMING CONFERENCES

CGTWC AND CRDWC

September, 2027

San Diego, CA, USA

ORGANIZED BY:

PRECISION GLOBAL CONFERENCES

Interested in participating as a speaker or listener?

Phone: +1-571-5561014

E-mail: info@precisionglobalconferences.com